Statement: There were no instances of patients with abnormal heart rates in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 3/31 (9.68%)   Edema: limb * 2/31 (6.45%)   Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%)   Cardiac General - Other (Specify, __) *  [1]0/31 (0.00%)   Cardiac General - Other (Specify, __) *  [2]0/31 (0.00%)   Left ventricular diastolic dysfunction * 0/31 (0.00%)   Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/31 (0.00%) Adverse Events 2:   Total: 8/25 (32.00%)   Edema: limb * 1/25 (4.00%)   Neutrophils/granulocytes (ANC/AGC) * 0/25 (0.00%)   Cardiac General - Other (Specify, __) *  [1]1/25 (4.00%)   Cardiac General - Other (Specify, __) *  [2]0/25 (0.00%)   Left ventricular diastolic dysfunction * 1/25 (4.00%)   Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%)